<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03397355</url>
  </required_header>
  <id_info>
    <org_study_id>Lung biopsy and biomarkers</org_study_id>
    <nct_id>NCT03397355</nct_id>
  </id_info>
  <brief_title>Monitoring the Changes of Tumor-related Biomarkers Before and After Pulmonary Nodule Biopsy.</brief_title>
  <official_title>Changes of Tumor-related Biomarkers Before and After Pulmonary Nodule Biopsy and Their Clinical Implications.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China-Japan Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>China-Japan Friendship Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the past few years, circulating tumor cells (CTCs), circulating tumor DNA (ctDNA),&#xD;
      microRNAs, autoantibodies, and T-cell receptor repertoire are new biomarkers of liquid biopsy&#xD;
      in cancer, which has been demonstrated to have a great value in diagnostics, treatment&#xD;
      evaluation, and prognosis prediction. However, most of previous data were based on late stage&#xD;
      tumor patients. This study plans to utilize the minimally invasive method to detect the&#xD;
      changes of numbers of CTCs, ctDNA hot spot mutations and methylation signals, microRNAs,&#xD;
      autoantibodies, and T-cell receptor repertoire in early stage lung cancer patients before and&#xD;
      after pulmonary nodule biopsy, during therapeutic and follow-up periods, in order to evaluate&#xD;
      the clinical values of above tumor-related biomarkers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Death or survival</measure>
    <time_frame>Baseline and every three- or six-month follow-up within two years for each patient.</time_frame>
    <description>Death or survival</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease progress</measure>
    <time_frame>Baseline and every three- or six-month follow-up within two years for each patient.</time_frame>
    <description>Complete Response(CR), Partial Response(PR), Stable Disease(SD), Progressive Disease(PD)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reasons of study termination</measure>
    <time_frame>Baseline and every three- or six-month follow-up within two years for each patient.</time_frame>
    <description>Complete the study, Lost to follow-up, Withdrawal of informed consent, Terminated by the investigator, Severe adverse event(SAE).</description>
  </primary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Lung Cancer</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood and tissue&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with pulmonary nodules (single or multiple) by CT scans.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed as suspected lung cancer patients with pulmonary nodules (single or&#xD;
             multiple) by CT scans, and the maximum diameter of nodule is between 8mm and 3cm;&#xD;
&#xD;
          -  Male or female, with age of 18~80 years;&#xD;
&#xD;
          -  Agree to take the pulmonary nodule biopsy, and sign the Informed Consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  With severe comorbidities and unable to participate in this study;&#xD;
&#xD;
          -  Diagnosed with acute respiratory tract infection, for instance fungus, mycobacterium&#xD;
             tuberculosis or other bacteria, virus, etc., one month prior to the study recruitment;&#xD;
&#xD;
          -  Pregnant or maternal women;&#xD;
&#xD;
          -  Diagnosed with other carcinoma, and the pulmonary nodules suspected of stemming from&#xD;
             other sites;&#xD;
&#xD;
          -  Unable for regular follow-ups according to the research protocol;&#xD;
&#xD;
          -  Blood sample is not qualified for biomarker testing.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chen WANG, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>China-Japan Friendship Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jieping LEI, Ph.D.</last_name>
    <phone>010-84206408</phone>
    <email>jiepinglei@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sinan WU, M.D.</last_name>
    <phone>010-84206408</phone>
    <email>tks0423@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>China-Japan Friendship Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jieping LEI, Ph.D.</last_name>
      <phone>010-84206408</phone>
      <email>jiepinglei@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>December 30, 2017</study_first_submitted>
  <study_first_submitted_qc>January 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 12, 2018</study_first_posted>
  <last_update_submitted>January 29, 2019</last_update_submitted>
  <last_update_submitted_qc>January 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>China-Japan Friendship Hospital</investigator_affiliation>
    <investigator_full_name>Chen Wang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Pulmonary Nodule; Lung Cancer; Biopsy; Biomarker.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Pulmonary Nodules</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

